Congenital CMV infection: Prevalence in newborns and the impact on hearing deficit

Engman, Mona-Lisa; Malm, Gunilla; Engstrom, L.; Petersson, Karin; Karltorp, Eva; Fahnehjelm, Kristina Teär; Uhlén, Inger; Guthenberg, Claes; Lewensohn-Fuchs, Ilona

doi:10.1080/00365540802308431

Cited by 48 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is comparable with the prevalence established in similar prospective studies in the neighboring countries of Italy (0.18%; 95% CI, 0.09-0.26%) [Barbi et al, 2006] and Austria (0.21%) [Halwaschs-Baumann et al, 2000], and some other industrialized countries such as Sweden (0.20%; 95% CI, 0.1-0.3%) [Engman et al, 2008], Japan (0.17-0.19%) [Yamagashi et al, 2006;Endo et al, 2009] and the Netherlands (0.09%; 95% CI, 0.04-0.19%) [Gaytant et al, 2005]. Some other studies from the above mentioned countries showed higher prevalence of congenital CMV infection (Italy 0.47%; 95% CI, 0.22-1.00% [Barbi et al, 1998], Sweden 0.46%; 95% CI, 0.37-0.58% [Ahlfors et al, 1999], Japan 0.66%; 95% CI, 0.27-1.70% [Kamada et al, 1983] and 0.31%; 95% CI, 0.22-0.43% [Numazaki and Fujikawa, 2004]), however, due to their design they may suffer from selection bias.…”

Section: Discussionsupporting

confidence: 93%

“…In similar previous studies, the prevalence at birth in Israel and Brasil were 0.7% and 1.1% (95% CI, 0.86-1.33%), respectively [Schlesinger et al, 2003;Mussi-Pinhata et al, 2009]. In the great majority of prevalence studies published to date, DBS have been used for PCR screening, prospectively or retrospectively [Barbi et al, 2006;Yamagashi et al, 2006;Engman et al, 2008;Boppana et al, 2010;Kharrazi et al, 2010]. PCR protocols for the detection of CMV DNA in DBS were first developed for retrospective diagnosis of congenital CMV infection in infants and children with hearing loss or other congenital CMV-related symptoms, which had not been diagnosed at birth [Johansson et al, 1997;Barbi et al, 2000Barbi et al, , 2006Yamamoto et al, 2001].…”

Section: Discussionmentioning

confidence: 82%

“…The prevalence of congenital CMV infection at birth, defined as the number of CMV infected newborns divided by the total number of live-born infants [Kenneson and Cannon, 2007], varies in the published literature between 0.2% and 2.2% [HalwaschsBaumann et al, 2000;Schlesinger et al, 2003;Barbi et al, 2006;Yamagashi et al, 2006;Engman et al, 2008;Inoue and Koyano, 2008;Soetens et al, 2008;Endo et al, 2009;Mussi-Pinhata et al, 2009;Boppana et al, 2010Boppana et al, , 2011. In contrast to high-income Western countries, reliable data on the prevalence of congenital CMV infection at birth in other parts of the world are quite scarce.…”

Section: Introductionmentioning

confidence: 99%

“…Congenital CMV infection is a leading non-genetic cause of sensorineural hearing loss in infants and children [American Academy of Pediatrics, 2007;Engman et al, 2008;Grosse et al, 2008]. Although sensorineural hearing loss can be detected by hearing screening of newborn, a substantial proportion of affected children are missed using this screening approach [Fowler et al, 1997;Foulon et al, 2008].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Paradiž

Seme

Puklavec

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

Human cytomegalovirus (CMV) is the most frequent cause of congenital infection in humans. In the first prevalence study of congenital CMV infection in Eastern and Central Europe, all neonates born in a 22-month period in two Slovenian maternity units (total of 2,841 newborns) were screened prospectively for congenital CMV infection by a real-time polymerase chain reaction (PCR) in urine. In all newborns with positive screening results, plasma and dried blood spots (DBS) collected at birth were tested additionally for CMV DNA. Congenital CMV infection was confirmed by virus isolation from a urine sample collected within the first 2 weeks of life. Congenital CMV infection was identified in four out of 2,841 newborns tested (incidence 0.14%; 95% CI, 0.05-0.39%). In four newborns with confirmed congenital infection, the concentration of CMV DNA in urine ranged from 4.68 to 8.18 log(10) copies/ml, all four newborns had detectable CMV DNA in plasma taken at birth (1.26-3.34 log(10) copies/ml) and two out of four had detectable CMV DNA in DBS collected during newborn metabolic screening. None of the four newborns with confirmed congenital CMV infection was symptomatic. The study showed that the prevalence of congenital CMV infection at birth in Slovenia is among the lowest in the world and that CMV DNA PCR testing of urine is a suitable and affordable real-time screening strategy for congenital CMV infection. If it is performed in 24 mini-pools, the cost of screening is 1.4 €/newborn and the cost of detecting a single newborn with congenital CMV infection 1,000 €.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Paradiž

Seme

Puklavec

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Studies employing a range of methods for CMV DBS testing have reported widely varying sensitivities of 50-100%. (Barbi et al 2008;Engman et al 2008;Soetens et al 2008;Choi et al 2009a, b) Some studies showing 100% sensitivity used DBS samples from infants already diagnosed with congenital CMV, either on clinical grounds or by culture techniques, which would overrepresent infants with higher CMV viral loads and thus produce artificially high estimates of sensitivity. Two DBS studies tested unselected samples of infants and also collected either urine or saliva for comparative testing and reported DBS testing sensitivities of 70-80% and specificities of 99-100%.…”

Section: Infrastructure and Laboratory Methods For CMV Newborn Screeningmentioning

confidence: 97%

Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus

Dollard

Schleiss

Grosse

2010

J of Inher Metab Disea

View full text Add to dashboard Cite

Congenital cytomegalovirus (CMV) infection is the most common infection in newborns worldwide and causes hearing loss and other neurological disability in 15-20% of infected infants. Only about half of the hearing loss resulting from congenital CMV infection is currently detected by universal newborn hearing screening because of late-onset hearing loss. Thus, much of the hearing loss and the majority of other CMV-associated disabilities remain undetected for years after birth and are never connected to CMV infection. Congenital CMV may be appropriate to include in national newborn screening (NBS) programs because it is more common than other disorders tested for by NBS programs and is a major cause of disability. Significant obstacles to the implementation of screening for congenital CMV include the lack of a standardized, high-throughput screening test and a protocol for follow-up of CMV-infected children. Nonetheless, screening newborns for congenital CMV infection merits further consideration.

show abstract

Congenital Cytomegalovirus Infection in Pediatric Hearing Loss

Misono¹,

Sie²,

Weiss³

et al. 2011

Arch Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Objectives To compare the prevalence of congenital cytomegalovirus (CMV) infection in Washington State in children with hearing loss (HL) and the general population and to compare the characteristics of HL in children with and without congenital CMV infection. Design Matched case-control; case cohort. Setting Regional pediatric hospital, Washington State Department of Health (WSDOH). Patients Cases were children 4 years and older with HL born in Washington State. Control individuals matched for demographic characteristics were identified at random through the WSDOH. Main Outcome Measures Congenital CMV status determined using quantitative polymerase chain reaction testing on newborn heel stick blood spots archived by the WSDOH. Audiologic data were used to characterize HL. Results Congenital CMV testing was performed for 222 matched cases and controls. Congenital CMV infection was detected in 1.4% of controls and in 9.9% of cases (odds ratio, 10.5; 95% confidence interval, 2.6–92.4). An estimated 8.9% of HL in children in Washington can be attributed to CMV infection. After inclusion of an additional 132 children with HL (for a total of 354 cases in the case cohort), we observed that children with congenital CMV had more severe HL(P<.001)and higher proportions of progressive (P=.02) and unilateral (P=.002) HL compared with children without congenital CMV infection. In the 35 children with congenital CMV infection, there was no relationship between neonatal CMV load and severity of HL. Conclusions In Washington State, children with HL had a far higher prevalence of congenital CMV viremia than did the general pediatric population, and CMV infection seems to be responsible for an appreciable fraction of pediatric HL in Washington State.

show abstract

Congenital CMV infection: Prevalence in newborns and the impact on hearing deficit

Cited by 48 publications

References 24 publications

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Prevalence of congenital cytomegalovirus infection in Slovenia: A study on 2,841 newborns

Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus

Congenital Cytomegalovirus Infection in Pediatric Hearing Loss

Contact Info

Product

Resources

About